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Background: Extra-nodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue originating in the
liver is less common.
Case presentation: We described the clinical presentation, immunohistochemistry, and immunophenotypes of this
lymphoma, which was misdiagnosed with tiny hepatic carcinoma in a 44-year-old woman with hepatitis C; the
patient underwent left lateral sectionectomy. The immunophenotype identified the most of the lymphoid cells as
positive CD20, CD34, Ki67, CD3, CD4, CD79a, CD45RO, MUM-1, and CD5 and negative CD10, CD15, CD30, ACT, CK,
CRO, DES, and HMB45. The diagnosis of primary hepatic mucosa-associated lymphoid tissue (MALT) was made by
histology after surgery; the patient went through the excellent recovery with no chemotherapy and is disease free
for 27 months.
Conclusions: Primary hepatic MALT is less common with incidental finding; local resection is beneficial due to its
oncological indolence.
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Left lateral sectionectomyBackground
In 1983, Isaacson et al. first described four patients with
primary low-grade hepatic B cell lymphoma of mucosa-
associated lymphoid tissue as a distinct entity [1]; later,
the lymphomas were sporadically reported and its preva-
lence is very low [2–4]. Jaffe documented that hepatic
malignant lymphomas comprised less than 1 % of all
malignant lymphomas, while hepatic mucosa-associated
lymphoid tissue (MALT) lymphomas are reported to
occur in only 3 % of cases of hepatic malignant lymph-
oma [5]. Due to the heterogeneous clinical presentations
and no specific manifestations of MALT, this lymphoma
was commonly misdiagnosed with liver cancer in the ab-
sence of biopsy [6, 7]. Herein, we first focused on a pri-
mary hepatic MALT-type lymphoma misdiagnosed as* Correspondence: wangh302h@126.com; liuz302h@126.com
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(HCV)-associated cirrhosis who underwent left lateral
sectionectomy.Case presentation
A 49-year-old female patient of Han Ethnicity presented
with mild distention pain in the right hypochondrium;
her disease history included hepatitis C for about
10 years, and at that time, liver functions test was per-
formed, revealing aminotransferase lightly beyond the
upper normal limit. On physical examination, laborator-
ies were significant for positive HCV antibody, quantita-
tive HCV RNA was 1.28 × 106 cope/ml, gene subtype is
1b, and no regular treatment of HCV was recorded.
Tumor biomarkers were unremarkable, including alpha
fetoprotein, carbohydrate antigens, and carcinoembryo-
nic antigen; autoimmune diseases test were negative,
and thyroid immunoglobulin was within the normalstributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
t to the original author(s) and the source, provide a link to the Creative
re made. The Creative Commons Public Domain Dedication waiver (http://
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Fig. 2 Portal phase extracellular Gd-chelate-enhanced MRI
demonstrating a T1 and T2 hypointense sphenoid lesion (arrow) in
the Sg 3 which is enhanced in the delayed phase, indicating a small
hepatocellular carcinoma
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intensity round mass of 1.8 cm in the segment 3 of the
liver which was enhanced in the early phase, clinically
indicating tiny hepatocellular carcinoma (Figs. 1 and 2).
Esphagogastroendoscopic findings indicated non-
atrophic gastritis with erosions, and it was negative for
Helicobacter pylori antibody. Polyp in the rectum was
detected with colon endoscope, and biopsy revealed the
inflammatory hyperplasia. The relevant cytogenetic test-
ing was not performed, liver biopsy was not used to de-
termine the imaging due to potential needle metastasis,
and no periphery lymphadenopathy and splenomegaly
were detected. Based on the history of chronic hepatitis
C infection and almost typical imaging character, the
diagnosis of tiny liver cancer was made, and left lateral
sectionectomy was performed. Later pathology deter-
mined the primary hepatic marginal zone B cell lymph-
oma of mucosa-associated lymphoid tissue type. Its
immunohistochemistry findings were positive for
CD20(+++), CD5(+), CD34(+), Ki67(30 %+), CD3(+),
CD4(++), CD79a(++), CD45RO(++), MUM-1(+++), and
fewer Kappa(+) whereas they were negative for CD8(−),
CD10(−), HBsAg(−), HBcAg(−), HCV(−), Hepa(−), GPC-
3(−), CD15(−), CD30, CD56(−), lambda(−), and CB2(−)
(Figs. 3 and 4). The patient experienced an uneventful
recovery course. According to Ann Arbor staging, it was
staged as IE. Chemotherapy was not applied even with
the informed consent. The patient received combination
of interferon β and ribavirin for 48 weeks, and HCV
DNA test was negative. Later, positron emissionFig. 1 MRI of the liver in a patient with chronic liver disease. Arterial
phase extracellular Gd-chelate-enhanced MRI demonstrating a T1
and T2 hyperintense sphenoid lesion of 1.8 cm (arrow) in diameter
in the Sg 3 which is enhanced in the early phase Fig. 3 Lymphoid cells infiltrated in the cirrhosis liver
Fig. 4 Most lymphoid cells positive for CD20 antibody
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thyroiditis was confirmed upon the elevation of thyroid
immunoglobulin. At follow-up, the woman was doing
well for over 2 years.
Discussion
The World Health Organization classified extra-nodal
MALT lymphomas as low-grade ones characterized by
their indolent, prolonged, localized, and clinical course
and potential curability with local amendments [8]. The
etiology of hepatic malignant lymphomas, especially
MALT lymphomas, remains unknown. It was reported
that Helicobacter pylori, hepatitis C virus, Epstein-Barr
virus, and Borrelia burgdorferi were demonstrated in as-
sociation with MALT lymphoma [9], and hepatitis C
virus infection played a role in the occurrence of MALT
reported by Ferri in 1993 [10]. Hashimoto’s thyroiditis
represents a background for the development of 94 % of
thyroid MALT lymphoma [11]. The molecular and cyto-
genetic data were very important, which not only con-
tributed to a correct diagnosis but also shed light on the
pathogenesis of this rare disease. The chromosomal
translocations in MALT lymphoma was detected, and
t(11;18)(q21;q21) is the most popular fusion signal in
MALT lymphoma. B cell non-Hodgkin’s lymphoma (B-
NHL) is a well-documented complication of HCVinfection. For our case with HCV, the test for H. pylorus
was negative, Hashimoto’s thyroiditis followed MALT,
and molecular and cytogenetic tests were unavailable
due to money budget in China. We think chronic in-
flammation by HCV hepatitis may involve many types of
cells including lymphocytes, and insidiously oncogenesis
occurs.
No specific immuno-histochemical marker has yet been
identified for MALT lymphoma. The presence of CD20(+)
is highly suggestive of lymphoma, and so is CD5(+) too.
CD5(+) allow us to differentiate chronic lymphocytic
leukemia from small lymphocytic lymphoma or mantle
cell lymphoma. Cyclin D1-positivity closely fits the charac-
teristics of classical, typical lymphocytic leukemia [12]. So,
the evaluation of a panel of immunostains is necessary for
the assessment of the architecture of the lymphoid infil-
trate, lineage assignment, and identification of an aberrant
phenotype and for the exclusion of other lymphomas and
facilitating differential diagnosis [13]. This report sug-
gested that clinicians should be concerned about the pos-
sibility of hepatic MALT in HCV patients with a hepatic
tumor as a differential diagnosis.
Generally, the prevalence of hepatic malignant lymph-
omas is extremely low, and it lacks specific clinical presen-
tations and biomarkers. The imaging feature was similar
to that of hepatocellular carcinoma (HCC), so it is com-
monly misjudged as an HCC [14] as well as, in our case,
misdiagnosed as tiny liver cancer, although there were no
findings to indicate a malignant lymphoma in systemic
screening and preemptive resection would confer greatly
on the patients. It is time to distinguish HCC from hepatic
malignant lymphoma by following their criteria [15].
Contrast-enhanced image studies including angiography,
dynamic CT, or Sonazoid-enhanced ultrasound might
bring effective findings to distinguish them. Most of the
time, biopsy works as the gold standard for the diagnosis
of liver tumors including MALT if necessary, though it
may spread tumors. To date, it needs warranting intensive
investigations and greater case accumulations.
Ann Arbor staging depends on both the place
where the malignant tissue is located and the sys-
temic symptoms due to the lymphoma. Staging and
classification guide the treatment options, and the
treatment of lymphoma (gastric) continues to evolve.
Disappearance of MALT-type lymphoma in patients
infected with HCV has been reported after anti-viral
treatment with interferon and ribavirin [16]. Low-
graded MALT is susceptible to resection while high-
graded MALT carries poor prognosis due to early
metastasis and low response to treatments. Our case
was staged IE which indicated chemotherapy is not
necessary, and no recurrence was detected for
27 months; long-lasting follow-up should be made to
monitor if the patient is disease free.
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tient for hepatectomy and potential publication of this
case report and any accompanying images.
Conclusions
Primary hepatic MALT is rare with incidental finding,
and local treatment may be beneficial due to its onco-
logical indolence.
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